Anti-T cell strategies in asthma

Inflammation Research

Volumn 48, Issue 10, 1999, Pages 516-523

  Kon, O M ^a   Kay, A B ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Anti T cell antibodies; CD4+ T cells; Chronic asthma; Immunomodulators; T cell peptides

Indexed keywords

CD4 ANTIGEN; CYCLOSPORIN A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 3; INTERLEUKIN 5; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; DEGRANULATION; EOSINOPHIL; HUMAN; PATHOGENESIS; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTHMA; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY;

EID: 0032743073     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050496     Document Type: Review

References (97)

1. Kay AB. Pathology of mild, severe, and fatal asthma. Am J Respir Crit Care Med 1996; 154: S66-9.
2. Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 1985; 131: 599-606.
3. Azzawi M, Bradley B, Jeffery PK, Frew AJ, Wardlaw AJ, Knowles G, et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990; 142: 1407-13.
4. Bentley AM, Meng Q, Robinson DS, Hamid Q, Kay AB, Durham SR. Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 1993; 8: 35-42.
5. Walker C, Kaegi MK, Braun P, Blaser K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol 1991; 88: 935-42.
6. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033-9.
7. + T cell lines in atopic asthmatics, and atopic and non-atopic controls. Eur J Immunol 1995; 25: 2727-31.
8. Walker C, Virchow JC Jr, Bruijnzeel PL, Blaser K. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol 1991; 146: 1829-35.
9. + T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997; 158: 3539-44.
10. Azzawi M, Johnston PW, Majumdar S, Kay AB, Jeffery PK. T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis 1992; 145: 1477-82.
11. Corrigan CJ, Hartnell A, Kay AB. T lymphocyte activation in acute severe asthma. Lancet 1988; 1: 1129-32.
12. Corrigan CJ, Kay AB. CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status. Am Rev Respir Dis 1990; 141: 970-7.
13. Robinson DS, Bentley AM, Hartnell A, Kay AB, Durham SR. Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax 1993; 48: 26-32.
14. Bentley AM, Hamid Q, Robinson DS, Schotman E, Meng Q, Assoufi B, et al. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996; 153: 551-6.
15. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145: 669-74.
16. Bentley AM, Maestrelli P, Saetta M, Fabbri LM, Robinson DS, Bradley BL, et al. Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J Allergy Clin Immunol 1992; 89: 821-9.
17. Bentley AM, Menz G, Storz C, Robinson DS, Bradley B, Jeffery PK, et al. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis 1992; 146: 500-6.
18. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC Jr. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992; 146: 109-15.
19. Durham SR. Late asthmatic responses. Respir Med 1990; 84: 263-8.
20. Sihra BS, Kon OM, Durham SR, Walker S, Barnes NC, Kay AB. Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax 1997; 52: 447-52.
21. Haselden BM, Kay AB, Larché M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999; 189: 1-10.
22. Anonymous. The British Guidelines on Asthma Management. Thorax 1997; 52: S1-S21.
23. Anonymous. International Consensus Report on Diagnosis and Treatment of Asthma. Clin Exp Allergy 1992; 22 Suppl 1: 1-72.
24. Medical Research Council. Controlled trial of cortisone acetate in status asthmaticus. Lancet 1956; ii: 803-6.
25. Medical Research Council. Controlled trial of effects of cortisone acetate in chronic asthma. Lancet 1956; ii: 798-803.
26. Barnes NC. Specific problems: steroid-induced side effects. In: O'Byrne P, Thomson NC, editors. Manual of asthma management. London: WB Saunders, 1995; 713-28.
27. Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989; 246: 1617-20.
28. Granelli Piperno A, Inaba K, Steinman RM. Stimulation of lymphokine release from T lymphoblasts. Requirement for mRNA synthesis and inhibition by cyclosporin A. J Exp Med 1984; 160: 1792-802.
29. Herold KC, Lancki DW, Moldwin RL, Fitch FW. Immunosuppressive effects of cyclosporin A on cloned T cells. J Immunol 1986; 136: 1315-21.
30. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-38.
31. Kaufmann Y, Chang AE, Robb RJ, Rosenberg SA. Mechanism of action of cyclosporin A: inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas. J Immunol 1984; 133: 3107-11.
32. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-42.
33. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-84.
34. Sowden JM, Berth Jones J, Ross JS, Motley RJ, Marks R, Finlay AY, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338: 137-40.
35. Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's relapse prevention trial investigators. N Engl J Med 1994; 330: 1846-51.
36. Yocum DE. Combination therapy with cyclosporin in rheumatoid arthritis. Br J Rheumatol 1996; 35 Suppl 2: 19-23.
37. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Int Med 1987; 107: 358-66.
38. + T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. Int Immunol 1995; 7: 449-57.
39. Sano T, Nakamura Y, Matsunaga Y, Takahashi T, Azuma M, Okano Y, et al. FK506 and cyclosporin A inhibit granulocyte/macrophage colony-stimulating factor production by mononuclear cells in asthma. Eur Respir J 1995; 8: 1473-8.
40. Triggiani M, Cirillo R, Lichtenstein LM, Marone G. Inhibition of histamine and prostaglandin D2 release from human lung mast cells by ciclosporin A. Int Arch Allergy Appl Immunol 1989; 88: 253-5.
41. Cirillo R, Triggiani M, Siri L, Ciccarelli A, Pettit GR, Condorelli M, et al. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 1990; 144: 3891-7.
42. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991; 174: 745-8.
43. Hatfield SM, Roehm NW. Cyclosporine and FK506 inhibition of murine mast cell cytokine production. J Pharmacol Exp Ther 1992; 260: 680-8.
44. Andersson J, Nagy S, Groth CG, Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology 1992; 75: 136-42.
45. Furue M, Katz SI. The effect of cyclosporine on epidermal cells. I. Cyclosporine inhibits accessory cell functions of epidermal Langerhans cells in vitro. J Immunol 1988; 140: 4139-43.
46. Arima M, Yukawa T, Terashi Y, Makino S. Effect of inhaled cyclosporin A on the allergen-induced late asthmatic response and increased in airway hyperresponsiveness in a guinea pig model of asthma. Arerugi 1994; 43: 1316-25.
47. Fukuda T, Akutsu I, Motojima S, Makino S. Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. Int Arch Allergy Appl Immunol 1991; 94: 259-61.
48. + T cells. Am J Respir Cell Mol Biol 1996; 14: 627-34.
49. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992; 339: 324-8.
50. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996; 153: 509-14.
51. Nizankowska E, Soja J, Pinis G, Bochenek G, Sladek K, Domagala B, et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995; 8: 1091-9.
52. Fukuda T, Asakawa J, Motojima S, Makino S. Cyclosporine A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma. Ann Allergy Asthma Immunol 1995; 75: 65-72.
53. Alexander AG, Barnes NC, Kay AB, Corrigan CJ. Clinical response to cyclosporin in chronic severe asthma is associated with reduction in serum soluble interleukin-2 receptor concentrations. Eur Respir J 1995; 8: 574-8.
54. Rodriguez F, Krayenbuhl JC, Harrison WB, Forre O, Dijkmans BA, Tugwell P, et al. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry. Arthritis Rheum 1996; 39: 1491-8.
55. Feutren G. The optimal use of cyclosporin A in autoimmune diseases [published erratum appeared in J Autoimmun 1992; 5: 545]. J Autoimmun 1992; 5 Suppl A: 183-95.
56. Alvarez FG, Knight C, Waldrep C, Rodarte JR, Knight V, Eschenbacher WL. Evaluation of the safety of cyclosporin A liposome aerosol in human subjects. Am J Respir Crit Care Med 1997; 155: A659.
57. O'Riordan TG, Iacono A, Keenan RJ, Duncan SR, Burckart GJ, Griffith BP, et al. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am J Respir Crit Care Med 1995; 151: 516-21.
58. Sablinski T, Hancock WW, Tilney NL, Kupiec Weglinski JW. CD4 monoclonal antibodies in organ transplantation - a review of progress. Transplantation 1991; 52: 579-89.
59. Choy EH, Kingsley GH. Anti-CD4 therapy in rheumatoid arthritis. Clin Exp Rheumatol 1993; 11 Suppl 8: S147-9.
60. Choy EH, Kingsley GH, Panayi GS. Treatment with anti-CD4 monoclonal antibody and acute interstitial nephritis. Arthritis Rheum 1993; 36: 723-4.
61. Herzog C, Walker C, Pichler W, Aeschlimann A, Wassmer P, Stockinger H, et al. Monoclonal anti-CD4 in arthritis [letter]. Lancet 1987; 2: 1461-2.
62. Moreland LW, Pratt PW, Sanders ME, Koopman WJ. Experience with a chimeric monoclonal anti-CD4 antibody in the treatment of refractory rheumatoid arthritis. Clin Exp Rheumatol 1993; 11 Suppl 8: S153-9.
63. van der Lubbe PA, Reiter C, Miltenburg AM, Kruger K, de Ruyter AN, Rieber EP, et al. Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody (cM-T412): immunopharmacological aspects and mechanisms of action. Scand J Immunol 1994; 39: 286-94.
64. van der Lubbe PA, Reiter C, Breedveld FC, Kruger K, Schattenkirchner M, Sanders ME, et al. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 1993; 36: 1375-9.
65. Wofsy D, Carteron NL. CD4 antibody therapy in systemic lupus erythematosus. Sem Immunol 1990; 2: 419-25.
66. Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998; 352: 1109-13.
67. + T cell counts. Arthritis Rheum 1994; 37: 834-8.
68. Keenan RJ, Konishi H, Kawai A, Paradis IL, Nunley DR, Iacono AT, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60: 580-4.
69. Bonham CA, Thomson AW. Immunosuppressants (Drugs and Monoclonal Antibodies). In: Kay AB, editor. Allergy and Allergic Diseases. Oxford: Blackwell Science, 1997; 642-66.
70. Sollinger HW. Update on preclinical and clinical experience with mycophenolate mofetil. Transplant Proc 1996; 28: 24-9.
71. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-32.
72. Briffa N, Morris RE. Immunosuppressive drugs after lung transplantation. Br Med J 1998; 316: 719-20.
73. Silva HTJ, Cao W, Shorthouse RA, Loffler M, Morris RE. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis. Transplant Proc 1997; 29: 1292-3.
74. Ramos EL, Nadler SG, Grasela DM, Kelley SL. Deoxyspergualin: mechanism of action and pharmacokinetics. Transplant Proc 1996; 28: 873-5.
75. Norman PS, Ohman JLJ, Long AA, Creticos PS, Gefter MA, Shaked Z, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154: 1623-8.
76. Pene J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus CF, et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 1998; 102: 571-8.
77. 2 induces specific T-cell energy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101: 747-54.
78. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996; 8: 1937-45.
79. Bolling SF, Lin H, Wei RQ, Turka LA. Preventing allograft rejection with CTLA41G: effect of donor-specific transfusion route or timing. J Heart Lung Transplant 1996; 15: 928-35.
80. Borish LC, Nelson HS, Lanz M, Claussen LR, Martin DW, Garrison L. Phase I/II study of interleukin-4 receptor in moderate asthma [abstract]. J Allergy Clin Immunol 1998; 101: S8
81. Coffman RL, Seymour BW, Hudak S, Jackson J, Rennick D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 1989; 245: 308-10.
82. Chand N, Harrison JE, Rooney S, Pillar J, Jakubicki R, Nolan K, et al. Anti-IL-5 monoclonal antibody inhibits allergic late phase bronchial eosinophilia in guinea pigs: a therapeutic approach. Eur J Pharmacol 1992; 211: 121-3.
83. Mauser PJ, Pitman AM, Fernandez X, Foran SK, Adams GK, Kreutner W, et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995; 152: 467-72.
84. Leckie MJ, ten Brinke A, Lordan J, Khan J, Diamant Z, Walls CJ, et al. SB240563 a humanized anti-IL-5 monoclonal antibody: initial single dose safety and activity in patients with asthma [abstract]. Am J Respir Crit Care Med 1999; 159.
85. Robinson DS, Durham SR, Kay AB. Cytokines in asthma. Thorax 1993; 48: 845-53.
86. Barnes PJ. Is there a role for immunotherapy in the treatment of asthma? Am J Respir Crit Care Med 1996; 154: 1227-8.
87. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995; 151: 969-74.
88. Djurup R. The subclass nature and clinical significance of the IgG antibody response in patients undergoing allergen-specific immunotherapy. Allergy 1985; 40: 469-86.
89. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973; 52: 472-82.
90. Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, Proud D, Meier HL, Naclerio RM, et al. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy [published erratum appeared in J Clin Invest 1986; 78: 1421]. J Clin Invest 1985; 76: 2247-53.
91. Rocklin RE, Sheffer AL, Greineder DK, Melmon KL. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med 1980; 302: 1213-9.
92. Nagaya H. Induction of antigen-specific suppressor cells in patients with hay fever receiving immunotherapy. J Allergy Clin Immunol 1985; 75: 388-94.
93. Rak S, Hallden G, Sorenson S, Margari V, Scheynius A. The effect of immunotherapy on T-cell subsets in peripheral blood and bronchoalveolar lavage fluid in pollen-allergic patients. Allergy 1993; 48: 460-5.
94. Tamir R, Castracane JM, Rocklin RE. Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesis. J Allergy Clin Immunol 1987; 79: 591-8.
95. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92: 644-51.
96. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97: 1356-65.
97. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Br Med J 1991; 302: 265-9.